Summary: DermaSensor is an FDA-cleared, handheld device designed to help clinicians assess the risk of skin cancer in suspicious skin lesions. It uses a combination of optical spectroscopy and artificial intelligence to analyze lesions and provide immediate risk assessment results. This tool aims to enhance clinical confidence, support timely referrals, and improve patient outcomes by offering an objective, non-invasive method for skin cancer evaluation.

Summary: Pantheon™ is an AI-powered pathology platform that offers an integrated solution for slide viewing, reading, and analysis. It is designed to improve the precision, efficiency, and consistency of cancer diagnosis by providing pathologists with advanced tools for identifying, grading, and classifying cancer. The platform supports seamless integration with digital pathology workflows and is compatible with major pathology systems.

Summary: CADDIE is a cloud-based artificial intelligence tool designed to support gastroenterologists during colonoscopy procedures. It integrates seamlessly into clinical workflows, offering features like polyp detection and characterization to assist in real-time decision-making. This technology aims to improve patient outcomes by providing a higher level of diagnostic accuracy and efficiency.

Summary: MAGENTIQ-COLO™ leverages artificial intelligence and machine learning to assist gastroenterologists in detecting polyps during colonoscopies, aiming to increase adenoma detection rates and reduce the miss rate of sessile serrated adenomas. With over 65 million frames processed and validated by a comprehensive study, the tool integrates into gastroenterology clinics to support clinical decision-making and improve the quality of colonoscopy procedures.

Summary: SKOUT by Iterative Health is designed to assist physicians during colorectal cancer screening and surveillance by providing real-time AI analysis. This tool aims to enhance the accuracy and efficiency of screenings, helping in the early detection and monitoring of colorectal cancer. By integrating advanced AI algorithms, SKOUT serves as an additional layer of analysis to support healthcare professionals in making more informed decisions.

Summary: Guardant Health offers a range of blood tests designed to provide critical insights for cancer care. These tests, including the Shield™ Blood Test, Guardant Complete®, and Guardant Infinity™, are used for cancer screening, as well as for guiding treatment decisions in patients with early and advanced-stage cancer. By analyzing circulating tumor DNA, Guardant Health's tests aim to improve clinical outcomes through precision oncology.

Summary: WRDensity leverages artificial intelligence to provide a more consistent assessment of breast density during mammography screenings. It is designed to integrate seamlessly with RIS/PACS systems and has been trained on over 600,000 images from the Mallinckrodt Institute of Radiology. This tool aims to create uniformity in density assessment at the practice level, improving the accuracy of breast cancer screenings.

Summary: Koios DS™ leverages artificial intelligence and machine learning to provide clinical decision support for the diagnosis of breast and thyroid cancer through ultrasound imaging. This software aims to improve diagnostic accuracy and efficiency, potentially leading to earlier detection and treatment. With FDA clearance and CE marking, Koios DS™ integrates into clinical workflows, offering a billable procedure that enhances both survival rates and workflow efficiency.

Summary: DERM (Deep Ensemble for the Recognition of Malignancy) is a Class III CE marked AI as a Medical Device (AIaMD) designed to improve skin cancer triage. It integrates with teledermatology platforms to accurately triage patients with non-cancerous lesions away from cancer pathways, optimizing dermatologist capacity for the most needed cases. This technology aims to enhance patient outcomes by ensuring timely and accurate skin cancer care.

Summary: AssureMDx is a urine-based test designed to help physicians identify patients with hematuria who are at increased risk for bladder cancer, facilitating timely referral to urology for further clinical evaluation. The test evaluates genomic changes associated with bladder cancer, including DNA methylation status and somatic mutation status of specific genes, to stratify patients by risk and potentially avoid unnecessary invasive procedures for those at low risk.